1
|
Ma P, Toussaint B, Roberti EA, Scornet N, Santos Silva A, Castillo Henríquez L, Cadasse M, Négrier P, Massip S, Dufat H, Hammad K, Baraldi C, Gamberini MC, Richard C, Veesler S, Espeau P, Lee T, Corvis Y. New Lidocaine-Based Pharmaceutical Cocrystals: Preparation, Characterization, and Influence of the Racemic vs. Enantiopure Coformer on the Physico-Chemical Properties. Pharmaceutics 2023; 15:pharmaceutics15041102. [PMID: 37111588 PMCID: PMC10142540 DOI: 10.3390/pharmaceutics15041102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2022] [Revised: 03/22/2023] [Accepted: 03/23/2023] [Indexed: 04/03/2023] Open
Abstract
This study describes the preparation, characterization, and influence of the enantiopure vs. racemic coformer on the physico-chemical properties of a pharmaceutical cocrystal. For that purpose, two new 1:1 cocrystals, namely lidocaine:dl-menthol and lidocaine:d-menthol, were prepared. The menthol racemate-based cocrystal was evaluated by means of X-ray diffraction, infrared spectroscopy, Raman, thermal analysis, and solubility experiments. The results were exhaustively compared with the first menthol-based pharmaceutical cocrystal, i.e., lidocaine:l-menthol, discovered in our group 12 years ago. Furthermore, the stable lidocaine/dl-menthol phase diagram has been screened, thoroughly evaluated, and compared to the enantiopure phase diagram. Thus, it has been proven that the racemic vs. enantiopure coformer leads to increased solubility and improved dissolution of lidocaine due to the low stable form induced by menthol molecular disorder in the lidocaine:dl-menthol cocrystal. To date, the 1:1 lidocaine:dl-menthol cocrystal is the third menthol-based pharmaceutical cocrystal, after the 1:1 lidocaine:l-menthol and the 1:2 lopinavir:l-menthol cocrystals reported in 2010 and 2022, respectively. Overall, this study shows promising potential for designing new materials with both improved characteristics and functional properties in the fields of pharmaceutical sciences and crystal engineering.
Collapse
Affiliation(s)
- Panpan Ma
- CNRS, INSERM, UTCBS, Chemical and Biological Technologies for Health Group, Université Paris Cité, F-75006 Paris, France
| | - Balthazar Toussaint
- CNRS, INSERM, UTCBS, Chemical and Biological Technologies for Health Group, Université Paris Cité, F-75006 Paris, France
- Département Recherche et Développement Pharmaceutique (DRDP), Agence générale des Équipements et Produits de Santé, AP-HP, F-75005 Paris, France
| | - Enrica Angela Roberti
- CNRS, INSERM, UTCBS, Chemical and Biological Technologies for Health Group, Université Paris Cité, F-75006 Paris, France
| | - Noémie Scornet
- CNRS, INSERM, UTCBS, Chemical and Biological Technologies for Health Group, Université Paris Cité, F-75006 Paris, France
| | - Axel Santos Silva
- CNRS, INSERM, UTCBS, Chemical and Biological Technologies for Health Group, Université Paris Cité, F-75006 Paris, France
| | - Luis Castillo Henríquez
- CNRS, INSERM, UTCBS, Chemical and Biological Technologies for Health Group, Université Paris Cité, F-75006 Paris, France
| | - Monique Cadasse
- Département Physico-Chimie du Médicament, Unité Pédagogique de Chimie Analytique, Physique et Toxicologie, Faculté de Santé, Université Paris Cité, 4 Avenue de l’Observatoire, F-75006 Paris, France
| | - Philippe Négrier
- Laboratoire Ondes et Matière d’Aquitaine, Université de Bordeaux, UMR 5798, F-33400 Talence, France
| | - Stéphane Massip
- CNRS, INSERM, IECB, Université de Bordeaux, UAR 3033, F-33600 Pessac, France
| | - Hanh Dufat
- CiTCoM, Université Paris Cité, UMR CNRS 8038, F-75006 Paris, France
| | - Karim Hammad
- CiTCoM, Université Paris Cité, UMR CNRS 8038, F-75006 Paris, France
| | - Cecilia Baraldi
- Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy
| | | | - Cyrille Richard
- CNRS, INSERM, UTCBS, Chemical and Biological Technologies for Health Group, Université Paris Cité, F-75006 Paris, France
| | - Stéphane Veesler
- CNRS, Aix-Marseille Université, CINaM (Centre Interdisciplinaire de Nanosciences de Marseille), Campus de Luminy, CEDEX 09, F-13288 Marseille, France
| | - Philippe Espeau
- CNRS, INSERM, UTCBS, Chemical and Biological Technologies for Health Group, Université Paris Cité, F-75006 Paris, France
| | - Tu Lee
- Department of Chemical and Materials Engineering, National Central University, Taoyuan 320317, Taiwan
| | - Yohann Corvis
- CNRS, INSERM, UTCBS, Chemical and Biological Technologies for Health Group, Université Paris Cité, F-75006 Paris, France
- Correspondence:
| |
Collapse
|
2
|
Aker SŞ, Ağar E, Tinelli A, Hatirnaz S, Ortaç F. The Impact of HPV Diagnosis and Abnormal Cervical Cytology Results on Sexual Dysfunction and Anxiety. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2023; 20:3630. [PMID: 36834323 PMCID: PMC9966090 DOI: 10.3390/ijerph20043630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Revised: 02/04/2023] [Accepted: 02/17/2023] [Indexed: 06/18/2023]
Abstract
BACKGROUND The objective of this study is to evaluate the effect of HPV diagnosis on the sexual function and anxiety levels of Turkish women. METHODS A total of 274 female patients who tested positive with HPV were included in the study and categorized into four groups: Group 1 (HPV 16/18 with normal cytology), Group 2 (HPV 16/18 with abnormal cytology), Group 3 (other high-strain HPV with normal cytology), and Group 4 (other high-strain HPV with abnormal cytology). All patients filled out the Beck Anxiety Inventory (BAI) and Female Sexual Function Index (FSFI) at the time when they tested positive for HPV and during the two-month and six-month follow-ups. RESULTS Significant increases were observed in BAI scores in all four groups, whereas significant decreases were observed in total FSFI scores in Groups 1 and 2 only(p < 0.05). BAI scores of Groups 1 and 2 were significantly higher than those of Groups 3 and 4 (p < 0.05). FSFI scores of Groups 1 and 2 measured during the sixth-month follow-up were significantly decreased (p = 0.004 and p < 0.001, respectively). CONCLUSIONS Our findings suggest that patients with HPV 16 and 18 positivity and abnormal cytological findings are more likely to have high anxiety and sexual dysfunction.
Collapse
Affiliation(s)
- Seda Şahin Aker
- Department of Gynecology and Obstetrics, Gynecologic Oncology Division, Kayseri City Hospital, 38080 Kayseri, Turkey
| | - Eser Ağar
- Department of Vocational School of Health Services, Operating Room Services Division, Istanbul Gelisim University, 34570 Istanbul, Turkey
| | - Andrea Tinelli
- Department of Obstetrics and Gynecology and CERICSAL (CEntro di RIcercaClinicoSALentino), Verisdelli Ponti Hospital, 73020 Scorrano, Italy
| | - Safak Hatirnaz
- Medical Park Hospital, In Vitro Fertilization Unit, 55200 Samsun, Turkey
| | - Fırat Ortaç
- Department of Gynecology and Obstetrics, Gynecologic Oncology Division, Ankara University, 06100 Ankara, Turkey
| |
Collapse
|
3
|
Innovative Diagnostic and Therapeutic Interventions in Cervical Dysplasia: A Systematic Review of Controlled Trials. Cancers (Basel) 2022; 14:cancers14112670. [PMID: 35681649 PMCID: PMC9179487 DOI: 10.3390/cancers14112670] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Revised: 05/18/2022] [Accepted: 05/25/2022] [Indexed: 02/04/2023] Open
Abstract
Cervical dysplasia is a common precancerous lesion affecting 1% to 2% of women worldwide. Significant progress in the diagnosis and treatment of cervical dysplasia have been made in the last decade. We performed a systematic literature search of the databases PubMed and Cochrane Central Register of Controlled Trials to identify controlled clinical trials reporting on the efficacy and safety of diagnostic and therapeutic interventions for cervical dysplasia. Data were analyzed according to PRISMA guidelines. In total, 33 studies reporting on 5935 women were identified. We recommend intravenous or intracervical lidocaine for pain reduction during colposcopically-directed cervical biopsies but not topical lidocaine, music, or video colposcopy. Monsel’s solution might be used to control bleeding after cervical biopsies. The acetic acid test should be scored 1 min after the application of acetic acid and should be followed by Lugol’s iodine test for an optimal yield of LSIL/HSIL. LEEP/LLETZ remains the standard and techniques such as SWETZ, C-LETZ, and TCBEE are not superior. LEEP/LLETZ should be performed under local anesthesia and with direct colposcopic vision. Cryotherapy and thermoablation might be used in women with LSIL, especially in women with HIV infection, but LEEP/LLETZ remains the standard for HSIL. Topical imiquimod remains an experimental procedure. In conclusion, significant progress has been made in the last decade regarding both diagnostic interventions as well as therapeutic interventions for women with cervical dysplasia. Based on >30 controlled clinical trials, we were able to formulate specific and evidence-based recommendations.
Collapse
|